FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Michael Carducci

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Procedures

Physiology

Disease Progression

Co-author Network

Publications

TOP 3
Nwabundo Nwankwo; Lee Resta; Donald Thornton; Ting Wang; Zhe Zhang; Connie Collins; Jeannette Day; Rodney Decker; Sabine Ermisch; Lori Kornberg; Steven Nicol; Deborah K Armstrong; Michael A Carducci
Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics.
Emmanuel S Antonarakis; Justine Y Bruce; Steve Y Cho; Lyn M Dyster; Gerald J Fetterly; David G Hangauer; Michael R Harrison; Elisabeth I Heath; Min-Fun R Kwan; Edwin M Posadas; Gregory E Wilding; Evan Y Yu; Michael A Carducci
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.
Nilofer S Azad; Michael A Carducci; Arvind Dasari; Luis Alberto Diaz; Ross C Donehower; Manuel Hidalgo; Daniel Laheru; Martine McManus; Kevin Quackenbush; MICHELLE RUDEK-RENAUT; Gretchen E Taylor; John J Wright; Ming Zhao; John Arcaroli; Wells A Messersmith
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Michael Carducci (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Nwabundo Nwankwo; Lee Resta; Donald Thornton; Ting Wang; Zhe Zhang; Connie Collins; Jeannette Day; Rodney Decker; Sabine Ermisch; Lori Kornberg; Steven Nicol; Deborah K Armstrong; Michael A Carducci
Phase I study of enzastaurin and bevacizumab in patients with advanced cancer: safety, efficacy and pharmacokinetics.
Investigational new drugs 2013;31(3):653-60.
2013: Emmanuel S Antonarakis; Justine Y Bruce; Steve Y Cho; Lyn M Dyster; Gerald J Fetterly; David G Hangauer; Michael R Harrison; Elisabeth I Heath; Min-Fun R Kwan; Edwin M Posadas; Gregory E Wilding; Evan Y Yu; Michael A Carducci
A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer.
Cancer chemotherapy and pharmacology 2013;71(4):883-92.
2013: Nilofer S Azad; Michael A Carducci; Arvind Dasari; Luis Alberto Diaz; Ross C Donehower; Manuel Hidalgo; Daniel Laheru; Martine McManus; Kevin Quackenbush; MICHELLE RUDEK-RENAUT; Gretchen E Taylor; John J Wright; Ming Zhao; John Arcaroli; Wells A Messersmith
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.
Investigational new drugs 2013;31(2):345-54.
2013: CLAIRE SNYDER; Antonio C Wolff; Albert W Wu; Amanda L Blackford; Michael A Carducci; JOSEPH HERMAN
Feasibility and value of PatientViewpoint: a web system for patient-reported outcomes assessment in clinical practice.
Psycho-oncology 2013;22(4):895-901.
2013: CLAIRE SNYDER; Antonio C Wolff; Amanda Blackford; Michael A Carducci; Kevin D Frick; Robert Herbert; Bridget A Neville; Craig C Earle
Quality of care for comorbid conditions during the transition to survivorship: differences between cancer survivors and noncancer controls.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(9):1140-8.
2013: Michel D Wissing; Michael A Carducci; Hans Gelderblom; Paulus van Diest
Tales of how great drugs were brought down by a flawed rationale--letter.
Clinical cancer research : an official journal of the American Association for Cancer Research 2013;19(5):1303.
2013: C J Paller; R P Roper; P R Sieber; B R Stockton; P J Wozniak; X Ye; M D Efros; B K Gillespie; R H Greengold; B L Hertzman; H R Liker; Michael A Carducci
A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer.
Prostate cancer and prostatic diseases 2013;16(1):50-5.
2013: Glenn Liu; Michael Pins; Mark Stein; Glenn J Bubley; Michael A Carducci; Yu-Hui Chen; Robert Dipaola; Wei Huang; Jill Kolesar; George Wilding
Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer.
Urologic oncology 2013;31(2):211-8.
2013: Emmanuel S Antonarakis; Amanda L Blackford; A Seun Ajiboye; Daniel C Danila; Anja Frost; Elisabeth I Heath; Sushant Kachhap; Serina King; Janet Mendonca; Dana Rathkopf; Michelle A Rudek; David C Smith; Ming Zhao; Michael A Carducci
Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer.
The oncologist 2013;18(2):163-73.
2013: Michael T Schweizer; Michael A Carducci
From bevacizumab to tasquinimod: angiogenesis as a therapeutic target in prostate cancer.
Cancer journal (Sudbury, Mass.) 2013;19(1):99-106.
2012: Emmanuel S Antonarakis; Michael A Carducci; Angelo M DeMarzo; Helen L Fedor; Bora Gurel; Jessica L Hicks; Daniel Keizman; Tamara LEVIN Lotan; Zhe Zhang; Mario A Eisenberger
An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.
Cancer 2012;118(24):6063-71.
2012: Steve Y Cho; Robert F Dannals; Mario A Eisenberger; Christopher J Endres; Kenneth L Gage; Daniel P Holt; Akimosa Jeffrey-Kwanisai; Alan P Kozikowski; MARTIN LODGE; RONNIE MEASE; Ronald Rodriguez; Camilo Rojas; Srinivasan Senthamizhchelvan; George Sgouros; Barbara Slusher; Michael A Carducci; Martin G Pomper
Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2012;53(12):1883-91.
2012: Jatinder Goyal; Peng Huang; Philipp Nuhn; Daniel Oh; Prachi Tyagi; Michael A Carducci; Mario A Eisenberger; Emmanuel S Antonarakis
The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer.
BJU international 2012;110(11 Pt B):E575-82.
2012: Alcides Chaux; Hans-Joerg Hammers; Jessica Hicks; Jenny J Kim; Roula Albadine; Mohamad E Allaf; Pedram Argani; Michael A Carducci; Victor E Reuter; Ronald Rodriguez; Luciana Schultz; GEORGES NETTO
Immunoexpression status and prognostic value of mammalian target of rapamycin and hypoxia-induced pathway members in papillary cell renal cell carcinomas.
Human pathology 2012;43(12):2129-37.
2012: Michael J Morris; Roberto Pili; Dana Elizabeth Rathkopf; Howard I Scher; Susan F Slovin; M Vincent; J J Chudow; Samuel R Denmeade; Mario A Eisenberger; J Farrelly; Michael A Carducci
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2012;23(10):2714-9.
2012: Elizabeth Hughes; Michael A Carducci; Albert W Wu; CLAIRE SNYDER
What can I do? Recommendations for responding to issues identified by patient-reported outcomes assessments used in clinical practice.
The journal of supportive oncology 2012;10(4):143-8.
2012: Samuel R Denmeade; Craig Dionne; Bora Gurel; W Nathaniel Brennen; Michael A Carducci; S Brøgger Christensen; Ingrid Dach; Susan L Dalrymple; Angelo M DeMarzo; Annastasiah Mhaka; Jesper V Møller; Poul Nissen; Claus Olesen; D Marc Rosen; George Wilding; John T Isaacs
Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy.
Science translational medicine 2012;4(140):140ra86.
2012: Glenn Liu; Michael A Carducci; Yu-Hui Chen; Robert Dipaola; George Wilding
Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group.
Clinical genitourinary cancer 2012;10(2):99-105.
2012: William Kevin Kelly; John F Mahoney; J Paul Monk; Michael Morris; Michael A Carducci; Daniel George; Susan Halabi; Philip Kantoff; Ellen Kaplan; Walter M Stadler; Nicholas J Vogelzang; Eric J Small
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(13):1534-40.
2012: Daniel Keizman; Svetlana Kovel; Natalie Maimon; Avivit Peer; Roberto Pili; Avishay Sella; Victoria Sinibaldi; Mario A Eisenberger; Maya Gottfried; Hans-Joerg Hammers; Henry Hayat; Maya Ish-Shalom; Raanan Berger; Ben Boursi; Michael A Carducci
Bisphosphonates combined with sunitinib may improve the response rate, progression free survival and overall survival of patients with bone metastases from renal cell carcinoma.
European journal of cancer (Oxford, England : 1990) 2012;48(7):1031-7.
2012: Robert J Motzer; Thomas Olencki; Roberto Pili; Thomas W Ratliff; Bruce G Redman; Cary N Robertson; Charles J Ryan; Joel Sheinfeld; Jue Wang; Richard B Wilder; Neeraj Agarwal; Clair Beard; Sam Bhayani; Graeme B Bolger; Mark K. Buyyounouski; Michael A Carducci; Sam S Chang; Toni K Choueiri; Shilpa Gupta; Steven L Hancock; Gary R Hudes; Eric Jonasch; Timothy M Kuzel; Clayton Lau; Ellis G Levine; Daniel W Lin; Kim A Margolin; M Dror Michaelson
Testicular cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2012;10(4):502-35.
2012: Emmanuel S Antonarakis; Michael A Carducci
Targeting angiogenesis for the treatment of prostate cancer.
Expert opinion on therapeutic targets 2012;16(4):365-76.
2012: Daniel J Zabransky; Marianna Zahurak; Michael A Carducci; Charles G Drake; Mario A Eisenberger; Daniel Keizman; Douglas G McNeel; Heath A Smith; Christopher J Thoburn; Emmanuel S Antonarakis
Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.
The Prostate 2012;72(5):487-98.
2012: Justine Yang Bruce; Michael A Carducci; Jens Eickhoff; Theodore Logan; Roberto Pili; Anthony Treston; George Wilding; Jamie Arnott; Glenn Liu
A phase II study of 2-methoxyestradiol nanocrystal colloidal dispersion alone and in combination with sunitinib malate in patients with metastatic renal cell carcinoma progressing on sunitinib malate.
Investigational new drugs 2012;30(2):794-802.
2012: Ajjai Alva; Michael A Carducci; Alice Chen; Kathleen Cooney; Stephanie Daignault; Robert Dipaola; Kenneth J Pienta; Susan Slovin; David C Smith; David Agus; Maha Hussain
Phase II study of cilengitide (EMD 121974, NSC 707544) in patients with non-metastatic castration resistant prostate cancer, NCI-6735. A study by the DOD/PCF prostate cancer clinical trials consortium.
Investigational new drugs 2012;30(2):749-57.
2012: Emmanuel S Antonarakis; Michael A Carducci; Daniel Keizman; Jianqing Lin; Marianna L Zahurak; Mario A Eisenberger
Changes in PSA kinetics predict metastasis- free survival in men with PSA-recurrent prostate cancer treated with nonhormonal agents: combined analysis of 4 phase II trials.
Cancer 2012;118(6):1533-42.
2012: Roisin M Connolly; Michael A Carducci; Emmanuel S Antonarakis
Use of androgen deprivation therapy in prostate cancer: indications and prevalence.
Asian journal of andrology 2012;14(2):177-86.
2012: Emmanuel S Antonarakis; Michael A Carducci; Samuel R Denmeade; Mario A Eisenberger; Kathy Jelaca-Maxwell; Howard I Scher; Susan F Slovin; Martha E Vincent; Michael J Morris
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial.
Cancer chemotherapy and pharmacology 2012;69(3):763-71.
2012: Daniel Keizman; Peng Huang; Michael A Carducci; Mario A Eisenberger
Contemporary experience with ketoconazole in patients with metastatic castration-resistant prostate cancer: clinical factors associated with PSA response and disease progression.
The Prostate 2012;72(4):461-7.
2012: Shabana Shabbeer; Brian W Simons; Simon A Williams; James G Herman; Michael A Carducci
Progression of prostate carcinogenesis and dietary methyl donors: temporal dependence.
Cancer prevention research (Philadelphia, Pa.) 2012;5(2):229-39.
2012: Roberto Pili; Michael A Carducci; S Altiok; Ming Zhao; J Zwiebel; DI QIAN; Brenda Salumbides; M A Rudek
Phase I study of the histone deacetylase inhibitor entinostat in combination with 13-cis retinoic acid in patients with solid tumours.
British journal of cancer 2012;106(1):77-84.
2012: Norma Kanarek; Dare Olatoye; Marty S Kanarek; Michael A Carducci
Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study.
Trials 2012;13():237.
2012: Abhinav Sidana; Muwen Wang; Shabana Shabbeer; Michael A Carducci; Wasim H Chowdhury; Shawn E Lupold; George Netto; Ronald Rodriguez
Mechanism of growth inhibition of prostate cancer xenografts by valproic acid.
Journal of biomedicine & biotechnology 2012;2012():180363.
2012: Channing J Paller; Michael A Carducci; George K Philips
Management of bone metastases in refractory prostate cancer--role of denosumab.
Clinical interventions in aging 2012;7():363-72.
2012: Daniel Keizman; Svetlana Kovel; Natalie Maimon; Avivit Neumann; Avivit Peer; Roberto Pili; Eli Rosenbaum; Michael A Carducci; Mario A Eisenberger; Maya Gottfried; Hans-Joerg Hammers; Maya Ish-Shalom; Victoria Sinibaldi; Avishay Sella
Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram.
The oncologist 2012;17(12):1508-14.
2012: Daniel Keizman; Hans-Joerg Hammers; Peng Huang; Maya Ish-Shalom; Roberto Pili; Mario A Eisenberger; Michael A Carducci
The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.
European journal of cancer (Oxford, England : 1990) 2012;48(2):202-8.
2012: Emmanuel S Antonarakis; Elizabeth B Humphreys; Patrick C Walsh; Michael A Carducci; Zhaoyong Feng; Alan W Partin; Bruce J Trock; Mario A Eisenberger
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up.
BJU international 2012;109(1):32-9.
2011: Daniel Keizman; Jenny J Kim; Victoria Sinibaldi; JANET WALCZAK; Emmanuel S Antonarakis; Michael A Carducci; Samuel R Denmeade; Peng Huang; Mario A Eisenberger
The change of PSA doubling time and its association with disease progression in patients with biochemically relapsed prostate cancer treated with intermittent androgen deprivation.
The Prostate 2011;71(15):1608-15.
2011: Jianqing Lin; Victoria Sinibaldi; Danny Y Song; Michael A Carducci; Samuel R Denmeade; Theodore L DeWeese; Mario A Eisenberger
Phase I trial with a combination of docetaxel and ¹⁵³Sm-lexidronam in patients with castration-resistant metastatic prostate cancer.
Urologic oncology 2011;29(6):670-5.
2011: Roberto Pili; Walter M Stadler; Vasileios J Assikis; Anders Björk; Michael A Carducci; Goran Forsberg; Jeffrey R Gingrich; Michael Häggman; Orjan Nordle; Andrew J Armstrong
Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(30):4022-8.
2011: Luciana Schultz; Victor E Reuter; Ronald Rodriguez; Roula Albadine; Mohamad E Allaf; Pedram Argani; Michael A Carducci; Alcides Chaux; Angelo M DeMarzo; Hans-Joerg Hammers; Jessica Hicks; Jenny J Kim; GEORGES NETTO
Immunoexpression status and prognostic value of mTOR and hypoxia-induced pathway members in primary and metastatic clear cell renal cell carcinomas.
The American journal of surgical pathology 2011;35(10):1549-56.
2011: Saby George; Michael A Carducci; Roberto Pili; Jenny J Kim
Role of immunotherapy for renal cell cancer in 2011.
Journal of the National Comprehensive Cancer Network : JNCCN 2011;9(9):1011-8.
2011: Robert J Motzer; Thomas Olencki; Roberto Pili; Thomas W Ratliff; Bruce G Redman; Cary N Robertson; Charles J Ryan; Joel Sheinfeld; Philippe E Spiess; Jue Wang; Richard B Wilder; Neeraj Agarwal; Clair Beard; Sam Bhayani; Graeme B Bolger; Michael A Carducci; Sam S Chang; Toni K Choueiri; Steven L Hancock; Gary R Hudes; Eric Jonasch; David Josephson; Timothy M Kuzel; Ellis G Levine; Daniel W Lin; Kim A Margolin; M Dror Michaelson
Kidney cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2011;9(9):960-77.
2011: Daniel Keizman; Jenny J Kim; Roberto Pili; Emmanuel S Antonarakis; Mario A Eisenberger; Hans-Joerg Hammers; Peng Huang; Michael A Carducci
Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: a retrospective examination.
European journal of cancer (Oxford, England : 1990) 2011;47(13):1955-61.
2011: CLAIRE SNYDER; Amanda Blackford; Michael A Carducci; Kevin D Frick; Robert Herbert; Bridget A Neville; Craig C Earle
Preventive care in prostate cancer patients: following diagnosis and for five-year survivors.
Journal of cancer survivorship : research and practice 2011;5(3):283-91.
2011: Himisha Beltran; Michael A Carducci; Johann de Bono; Martin Gleave; Maha Hussain; William K Kelly; Fred Saad; Cora Sternberg; Scott T Tagawa; Tomasz M Beer; Ian F Tannock
New therapies for castration-resistant prostate cancer: efficacy and safety.
European urology 2011;60(2):279-90.
2011: Evan Y Yu; Christophe Massard; Mitchell E Gross; Michael A Carducci; Stephane Culine; Gary Hudes; Edwin M Posadas; Cora N Sternberg; George Wilding; Géralyn C Trudel; Prashni Paliwal; Karim Fizazi
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer.
Urology 2011;77(5):1166-71.
2011: Frederick J Meyers; Michael A Carducci; Matthew J Loscalzo; John Linder; Tamara Greasby; Laurel Beckett
Effects of a problem-solving intervention (COPE) on quality of life for patients with advanced cancer on clinical trials and their caregivers: simultaneous care educational intervention (SCEI): linking palliation and clinical trials.
Journal of palliative medicine 2011;14(4):465-73.
2011: CLAIRE SNYDER; Amanda Blackford; Neil K Aaronson; Symone B Detmar; Michael A Carducci; Michael D Brundage; Albert W Wu
Can patient-reported outcome measures identify cancer patients' most bothersome issues?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(9):1216-20.
2011: Karim Fizazi; Michael A Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawrence Karsh; Piotr Milecki; Neal Shore; Michael Rader; Huei Wang; Qi Jiang; Sylvia Tadros; Roger Dansey; Carsten Goessl
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Lancet 2011;377(9768):813-22.
2011: Jianqing Lin; Michael C Haffner; YONGGANG ZHANG; Byron H Lee; W Nathaniel Brennen; Justin Britton; Sushant Kachhap; Joong Sup Shim; Jun O Liu; William G Nelson; Srinivasan Yegnasubramanian; Michael A Carducci
Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth.
The Prostate 2011;71(4):333-43.
2011: Dana Elizabeth Rathkopf; Glenn Liu; Michael A Carducci; Mario A Eisenberger; Aseem Anand; Michael J Morris; Susan F Slovin; Yasutsuna Sasaki; Shunji Takahashi; Seiichiro Ozono; Nga Kit Eliza Fung; Shinta Cheng; Jinping Gan; Marco Gottardis; Mary T Obermeier; Jyotsna Reddy; S Zhang; Blisse J Vakkalagadda; Leila Alland; George Wilding; Howard I Scher
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(4):880-7.
2011: Gary R Hudes; Michael A Carducci; Toni K Choueiri; Peg Esper; Eric Jonasch; Rashmi Kumar; Kim A Margolin; M Dror Michaelson; Robert J Motzer; Roberto Pili; Susan Roethke; Sandy Srinivas
NCCN Task Force report: optimizing treatment of advanced renal cell carcinoma with molecular targeted therapy.
Journal of the National Comprehensive Cancer Network : JNCCN 2011;9 Suppl 1():S1-29.
2011: Lee P Resta; Roberto Pili; Mario A Eisenberger; Avery Spitz; Serina King; Jennifer Porter; Amy Franke; Ramesh Boinpally; Michael A Carducci; Christopher J Sweeney
A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone.
Cancer chemotherapy and pharmacology 2011;67(2):431-8.
2011: Luis Alberto Diaz; Wells A Messersmith; Lori J Sokoll; Victoria Sinibaldi; Sandy Moore; Michael A Carducci; Mario A Eisenberger
TNF-blockade in patients with advanced hormone refractory prostate cancer.
Investigational new drugs 2011;29(1):192-4.
2011: Leigh Ellis; Kristin Lehet; Song Liu; Kiersten M Miles; Remi Adelaiye; Peter Atadja; Michael A Carducci; Swathi Ramakrishnan; Dan Wang; Roberto Pili
Concurrent HDAC and mTORC1 inhibition attenuate androgen receptor and hypoxia signaling associated with alterations in microRNA expression.
PloS one 2011;6(11):e27178.
2011: Abhinav Sidana; Muwen Wang; Wasim H Chowdhury; Antoun Toubaji; Shabana Shabbeer; George Netto; Michael A Carducci; Shawn E Lupold; Ronald Rodriguez
Does valproic acid induce neuroendocrine differentiation in prostate cancer?
Journal of biomedicine & biotechnology 2011;2011():607480.
2011: Joshua K Napora; Ryan G Short; Denis C Muller; Olga Carlson; Juliana O Odetunde; Xiaoqiang Xu; Michael A Carducci; Thomas G Travison; Marcello Maggio; Josephine M Egan; Shehzad Basaria
High-dose isoflavones do not improve metabolic and inflammatory parameters in androgen-deprived men with prostate cancer.
Journal of andrology 2011;32(1):40-8.
2010: Emmanuel S Antonarakis; Michael A Carducci
Future directions in castrate-resistant prostate cancer therapy.
Clinical genitourinary cancer 2010;8(1):37-46.
2010: Wells A Messersmith; Antonio Jimeno; Heather A Jacene; Ming Zhao; Piotr Kulesza; Daniel Laheru; Yasmin Kahn; Alexander Spira; Janet Dancey; Christine A Iacobuzio-Donahue; Ross C Donehower; Michael A Carducci; MICHELLE RUDEK-RENAUT; Manuel Hidalgo
Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer.
Clinical colorectal cancer 2010;9(5):297-304.
2010: CLAIRE SNYDER; Kevin D Frick; Amanda L Blackford; Robert Herbert; Bridget A Neville; Michael A Carducci; Craig C Earle
How does initial treatment choice affect short-term and long-term costs for clinically localized prostate cancer?
Cancer 2010;116(23):5391-9.
2010: Daniel Keizman; Marianna Zahurak; Victoria Sinibaldi; Michael A Carducci; Samuel R Denmeade; Charles G Drake; Roberto Pili; Emmanuel S Antonarakis; Susan Hudock; Mario A Eisenberger
Lenalidomide in nonmetastatic biochemically relapsed prostate cancer: results of a phase I/II double-blinded, randomized study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(21):5269-76.
2010: Ryan M Franke; Michael A Carducci; MICHELLE RUDEK-RENAUT; Sharyn D Baker; Alex Sparreboom
Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4562-7.
2010: CLAIRE SNYDER; Roxanne E Jensen; Gail Geller; Michael A Carducci; Albert W Wu
Relevant content for a patient-reported outcomes questionnaire for use in oncology clinical practice: Putting doctors and patients on the same page.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2010;19(7):1045-55.
2010: Keith William Pratz; E Cho; Mark Levis; Judith E Karp; Steven D Gore; A MICHAEL MCDEVITT; A Stine; Ming Zhao; Sharyn D Baker; Michael A Carducci; John J Wright; MICHELLE RUDEK-RENAUT; B Douglas Smith
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.
Leukemia 2010;24(8):1437-44.
2010: CLAIRE SNYDER; Amanda Blackford; Julie R Brahmer; Michael A Carducci; Roberto Pili; Vered Stearns; Antonio C Wolff; Sydney M Dy; Albert W Wu
Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2010;19(6):837-45.
2010: Andrew J Armstrong; GEORGES NETTO; MICHELLE RUDEK-RENAUT; Susan Halabi; David P Wood Jr; Patricia A Creel; Kelly Mundy; S Lindsay Davis; Ting Wang; Roula Albadine; Luciana Schultz; Alan W Partin; Antonio Jimeno; Helen Fedor; Phillip G Febbo; Daniel J George; Robin Gurganus; Angelo M DeMarzo; Michael A Carducci
A pharmacodynamic study of rapamycin in men with intermediate- to high-risk localized prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(11):3057-66.
2010: Karynsa Cetin; Jennifer L Beebe; Jon P Fryzek; Richard Markus; Michael A Carducci
Recent time trends in the epidemiology of stage IV prostate cancer in the United States: analysis of data from the Surveillance, Epidemiology, and End Results Program.
Urology 2010;75(6):1396-404.
2010: Emmanuel S Antonarakis; Michael A Carducci; Mario A Eisenberger
Novel targeted therapeutics for metastatic castration-resistant prostate cancer.
Cancer letters 2010;291(1):1-13.
2010: CLAIRE SNYDER; K B Stein; B B Barone; KIMBERLY PEAIRS; Hsin-Chieh Yeh; R L Derr; Antonio C Wolff; Michael A Carducci; frederick brancati
Does pre-existing diabetes affect prostate cancer prognosis? A systematic review.
Prostate cancer and prostatic diseases 2010;13(1):58-64.
2010: Emmanuel S Antonarakis; Michael A Carducci
Combining low-dose cyclophosphamide with GM-CSF-secreting prostate cancer immunotherapy enhances antitumor immune effects.
Expert opinion on investigational drugs 2010;19(2):311-4.
2010: Sushant Kachhap; Nadine Rosmus; Spencer J Collis; Madeline Kortenhorst; Michel D Wissing; Mohammad Hedayati; Shabana Shabbeer; Janet Mendonca; Justin Deangelis; LUIGI MARCHIONNI; Jianqing Lin; Naseruddin Höti; Johan W R Nortier; Theodore L DeWeese; Hans-Joerg Hammers; Michael A Carducci
Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor.
PloS one 2010;5(6):e11208.
2010: Robert S DiPaola; Yu-Hui Chen; Mark Stein; David Vaughn; Linda Patrick-Miller; Michael A Carducci; Bruce Roth; Eileen White; George Wilding
A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899.
Journal of translational medicine 2010;8():20.
2009: J Lin; Samuel R Denmeade; Michael A Carducci
HIF-1alpha and calcium signaling as targets for treatment of prostate cancer by cardiac glycosides.
Current cancer drug targets 2009;9(7):881-7.
2009: Preetika Sharma; Amy B Wisniewski; Milena Braga-Basaria; Xiaoqiang Xu; Mary Yep; Samuel R Denmeade; Adrian S Dobs; Theodore L DeWeese; Michael A Carducci; Shehzad Basaria
Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy.
The Journal of urology 2009;182(5):2265-72.
2009: Emmanuel S Antonarakis; Elisabeth Iljas Heath; JANET WALCZAK; William G Nelson; Helen Fedor; Angelo M DeMarzo; Marianna L Zahurak; Steven Piantadosi; Andrew J Dannenberg; Robin T Gurganus; Sharyn D Baker; Howard L Parnes; Theodore L DeWeese; Alan W Partin; Michael A Carducci
Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(30):4986-93.
2009: Jianqing Lin; Jill Gilbert; MICHELLE RUDEK-RENAUT; James Zwiebel; Steven D Gore; Anchalee Jiemjit; Ming Zhao; Sharyn D Baker; Richard F Ambinder; James G Herman; Ross C Donehower; Michael A Carducci
A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(19):6241-9.
2009: CLAIRE SNYDER; Elizabeth Garrett-Mayer; Amanda L Blackford; Julie R Brahmer; Michael A Carducci; Roberto Pili; Vered Stearns; Antonio C Wolff; Sydney M Dy; Albert W Wu
Concordance of cancer patients' function, symptoms, and supportive care needs.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2009;18(8):991-8.
2009: Daniel Keizman; Michael A Carducci
Intermittent androgen deprivation--questions remain.
Nature reviews. Urology 2009;6(8):412-4.
2009: Robert J Motzer; Neeraj Agarwal; Clair Beard; Graeme B Bolger; Barry Boston; Michael A Carducci; Toni K Choueiri; Robert A Figlin; Mayer Fishman; Steven L Hancock; Gary R Hudes; Eric Jonasch; Anne Kessinger; Timothy M Kuzel; Paul H Lange; Ellis G Levine; Kim A Margolin; M Dror Michaelson; Thomas Olencki; Roberto Pili; Bruce G Redman; Cary N Robertson; Lawrence H Schwartz; Joel Sheinfeld; Jue Wang
NCCN clinical practice guidelines in oncology: kidney cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(6):618-30.
2009: Robert J Motzer; Neeraj Agarwal; Clair Beard; Graeme B Bolger; Barry Boston; Michael A Carducci; Toni K Choueiri; Robert A Figlin; Mayer Fishman; Steven L Hancock; Gary R Hudes; Eric Jonasch; Anne Kessinger; Timothy M Kuzel; Paul H Lange; Ellis G Levine; Kim A Margolin; M Dror Michaelson; Thomas Olencki; Roberto Pili; Bruce G Redman; Cary N Robertson; Lawrence H Schwartz; Joel Sheinfeld; Jue Wang
NCCN clinical practice guidelines in oncology: testicular cancer.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(6):672-93.
2009: Nancy Kass; Jeremy Sugarman; Amy M Medley; Linda A Fogarty; Holly A Taylor; Christopher K Daugherty; MARK EMERSON; Steven Goodman; Fay J Hlubocky; Herbert I Hurwitz; Michael A Carducci; Annallys Goodwin-Landher
An intervention to improve cancer patients' understanding of early-phase clinical trials.
IRB 2009;31(3):1-10.
2009: Wennuan Liu; Sari Laitinen; Sofia Khan; Mauno Vihinen; Jeanne Kowalski; Guoqiang Yu; Li Chen; Charles M Ewing; Mario A Eisenberger; Michael A Carducci; William G Nelson; Srinivasan Yegnasubramanian; Jun Luo; Yue Wang; Jianfeng Xu; William B Isaacs; Tapio Visakorpi; G Steven Bova
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.
Nature medicine 2009;15(5):559-65.
2009: Madeline Kortenhorst; Sumit Isharwal; Paulus van Diest; Wasim H Chowdhury; Cameron Marlow; Michael A Carducci; Ronald Rodriguez; Robert W Veltri
Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo.
Molecular cancer therapeutics 2009;8(4):802-8.
2009: Jianqing Lin; Michael A Carducci
HIF-1alpha inhibition as a novel mechanism of cardiac glycosides in cancer therapeutics.
Expert opinion on investigational drugs 2009;18(2):241-3.
2009: Shabana Shabbeer; Michelle Sobolewski; RAVI ANCHOORI; Sushant Kachhap; Manuel Hidalgo; Antonio Jimeno; Nancy E Davidson; Michael A Carducci; Saeed R Khan
Fenugreek: a naturally occurring edible spice as an anticancer agent.
Cancer biology & therapy 2009;8(3):272-8.
2009: S D Baker; Jaap Verweij; G A Cusatis; R H van Schaik; S Marsh; S J Orwick; Ryan Franke; S Hu; E G Schuetz; Vishal Lamba; Wells A Messersmith; Antonio C Wolff; Michael A Carducci; Alex Sparreboom
Pharmacogenetic pathway analysis of docetaxel elimination.
Clinical pharmacology and therapeutics 2009;85(2):155-63.
2009: Michael J Morris; Ethan Basch; George Wilding; Maha Hussain; Michael A Carducci; Celestia S Higano; Philip Kantoff; William K Oh; Eric J Small; Daniel George; Paul Mathew; Tomasz M Beer; Susan F Slovin; Charles Ryan; Christopher Logothetis; Howard I Scher
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.
Clinical genitourinary cancer 2009;7(1):51-7.
2008: Elisabeth Iljas Heath; David W Hillman; Ulka Nitin Vaishampayan; Shijie Sheng; Asfar S Azmi; Felicity WK Harper; Melvin Gaskins; Henry C Pitot; Winston Tan; S Percy Ivy; Roberto Pili; Michael A Carducci; Charles Erlichman; Glenn Liu
A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7940-6.
2008: Joshi J Alumkal; Zhe Zhang; Elizabeth B Humphreys; Christina Bennett; Leslie A Mangold; Michael A Carducci; Alan W Partin; Elizabeth Garrett-Mayer; Angelo M DeMarzo; James G Herman
Effect of DNA methylation on identification of aggressive prostate cancer.
Urology 2008;72(6):1234-9.
2008: Madeline Kortenhorst; Marianna Zahurak; Shabana Shabbeer; Sushant Kachhap; Nathan Galloway; Giovanni Parmigiani; Hendrik Verheul; Michael A Carducci
A multiple-loop, double-cube microarray design applied to prostate cancer cell lines with variable sensitivity to histone deacetylase inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(21):6886-94.
2008: Joel B Nelson; William Love; Joseph L Chin; Fred Saad; Claude C Schulman; Darryl J Sleep; Jiang Qian; Joyce Steinberg; Michael A Carducci
Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.
Cancer 2008;113(9):2478-87.
2008: Peter J O'Brien; Rajeev Ramanathan; Jonathan M Yingling; Jose Baselga; Mace L Rothenberg; Michael A Carducci; Thomas Daly; Dorothy Adcock; Michael Lahn
Analysis and variability of TGFbeta measurements in cancer patients with skeletal metastases.
Biologics : targets & therapy 2008;2(3):563-9.
2008: Nancy Kass; Holly A Taylor; Linda A Fogarty; Jeremy Sugarman; Steven Goodman; Annallys Goodwin-Landher; Michael A Carducci; Herbert Hurwitz
Purpose and benefits of early phase cancer trials: what do oncologists say? What do patients hear?
Journal of empirical research on human research ethics : JERHRE 2008;3(3):57-68.
2008: A C Hooker; A J Ten Tije; Michael A Carducci; James E Weber; Elizabeth Garrett-Mayer; H Gelderblom; W P McGuire; Jaap Verweij; Mats O Karlsson; S D Baker
Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements.
Clinical pharmacology and therapeutics 2008;84(1):111-8.
2008: Dana Elizabeth Rathkopf; Michael A Carducci; Michael J Morris; Susan F Slovin; Mario A Eisenberger; Roberto Pili; Samuel R Denmeade; Moshe Kelsen; Tracy Curley; Melinda Halter; Connie Collins; Martin Fleisher; Glenn Heller; Sharyn D Baker; Howard I Scher
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(18):2959-65.
2008: Claire Bonfils; Ann Kalita; Marja Dubay; Lillian L Siu; Michael A Carducci; Gregory Reid; Robert E Martell; Jeffrey M Besterman; Zuomei Li
Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3441-9.
2008: CLAIRE SNYDER; Elizabeth Garrett-Mayer; Julie R Brahmer; Michael A Carducci; Roberto Pili; Vered Stearns; Antonio C Wolff; Sydney M Dy; Albert W Wu
Symptoms, supportive care needs, and function in cancer patients: how are they related?
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2008;17(5):665-77.
2008: Lillian L Siu; Roberto Pili; Ignacio Duran; Wells A Messersmith; Eric X Chen; Rana Sullivan; Martha Maclean; Serina King; Shirley Brown; Gregory K Reid; Zuomei Li; Ann M Kalita; Eric J Laille; Jeffrey M Besterman; Robert E Martell; Michael A Carducci
Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(12):1940-7.
2008: Lance K Lassiter; Mohan K Tummala; Maha Hussain; Walter M Stadler; Daniel P Petrylak; Michael A Carducci
Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy.
Clinical genitourinary cancer 2008;6(1):31-5.
2008: Howard I Scher; Susan Halabi; Ian Tannock; Michael J Morris; Cora N Sternberg; Michael A Carducci; Mario A Eisenberger; Celestia S Higano; Glenn J Bubley; Robert Dreicer; Daniel P Petrylak; Philip W Kantoff; Ethan Basch; W Kevin Kelly; William D Figg; Eric J Small; Tomasz M Beer; George Wilding; Alison Martin; Maha Hussain
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(7):1148-59.
2008: Charles Rudin; Wanqing Liu; Apurva Desai; Theodore Karrison; Xuemin Jiang; Linda Janisch; Soma Das; Jacqueline Ramirez; Balasubramanian Poonkuzhali; Erin G Schuetz; Donna Lee Fackenthal; Peixian Chen; Deborah K Armstrong; Julie R Brahmer; Gini F Fleming; Everett E Vokes; Michael A Carducci; Mark J Ratain
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(7):1119-27.
2008: Jose Baselga; Mace L Rothenberg; Josep Tabernero; Joan Seoane; Thomas Daly; Ann Cleverly; Brandi Berry; Susanne K Rhoades; Chad A Ray; Jeffrey Fill; Daphne L Farrington; Lisa Anne Wallace; Jonathan M Yingling; Michael Lahn; Carlos L Arteaga; Michael A Carducci
TGF-beta signalling-related markers in cancer patients with bone metastasis.
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2008;13(2):217-36.
2008: Antonio Jimeno; MICHELLE RUDEK-RENAUT; W. PURCELL; Daniel Laheru; Wells A Messersmith; Janet Dancey; Michael A Carducci; Sharyn D Baker; Manuel Hidalgo; Ross C Donehower
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors.
Cancer chemotherapy and pharmacology 2008;61(3):423-33.
2008: Danil V Makarov; Elizabeth B Humphreys; Leslie A Mangold; Michael A Carducci; Alan W Partin; Mario A Eisenberger; Patrick C Walsh; Bruce J Trock
The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy.
The Journal of urology 2008;179(1):156-61; discussion 161-2.
2007: Ethan Basch; Mark R Somerfield; Tomasz M Beer; Michael A Carducci; Celestia S Higano; Maha Hussain; Howard I Scher
American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(33):5313-8.
2007: Michael A Carducci; Fred Saad; Per-Anders Abrahamsson; David P Dearnaley; Claude C Schulman; Scott A North; Darryl J Sleep; Jeffrey D Isaacson; Joel B Nelson
A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.
Cancer 2007;110(9):1959-66.
2007: Connie Collins; Michael A Carducci; Mario A Eisenberger; John T Isaacs; Alan W Partin; Roberto Pili; Victoria Sinibaldi; JANET WALCZAK; Samuel R Denmeade
Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpoint.
Cancer biology & therapy 2007;6(9):1360-7.
2007: Andrew J Armstrong; Elizabeth Garrett-Mayer; Yi-Chun Ou Yang; Michael A Carducci; Ian Tannock; Ronald de Wit; Mario A Eisenberger
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(25):3965-70.
2007: CLAIRE SNYDER; Sydney M Dy; Danetta E Hendricks; Julie R Brahmer; Michael A Carducci; Antonio C Wolff; Albert W Wu
Asking the right questions: investigating needs assessments and health-related quality-of-life questionnaires for use in oncology clinical practice.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2007;15(9):1075-85.
2007: Hendrik Verheul; Zheng (David) Qian; Michael A Carducci; Roberto Pili
Sequence-dependent antitumor effects of differentiation agents in combination with cell cycle-dependent cytotoxic drugs.
Cancer chemotherapy and pharmacology 2007;60(3):329-39.
2007: Shabana Shabbeer; Madeline Kortenhorst; Sushant Kachhap; Nathan Galloway; Ronald Rodriguez; Michael A Carducci
Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
The Prostate 2007;67(10):1099-110.
2007: Gary R Hudes; Michael A Carducci; Piotr Tomczak; Janice Dutcher; Robert Figlin; Anil Kapoor; Elzbieta Staroslawska; Jeffrey A Sosman; David McDermott; István Bodrogi; Zoran Kovacevic; Vladimir Lesovoy; Ingo G H Schmidt-Wolf; Olga Barbarash; Erhan Gokmen; Timothy O'Toole; Stephanie Lustgarten; Laurence Moore; Robert J Motzer
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
The New England journal of medicine 2007;356(22):2271-81.
2007: Shaoyu Zhou; Sushant Kachhap; Wenyue Sun; Guojun Wu ; Alice Chuang; Luana Poeta; Lawson Grumbine; Suhail K Mithani; Aditi Chatterjee; Wayne M Koch; William H Westra; Anirban Maitra; Chad Glazer; Michael A Carducci; David Sidransky; Thomas McFate; Ajay Verma; Joseph A Califano
Frequency and phenotypic implications of mitochondrial DNA mutations in human squamous cell cancers of the head and neck.
Proceedings of the National Academy of Sciences of the United States of America 2007;104(18):7540-5.
2007: Shehzad Basaria; Denis C Muller; Michael A Carducci; Josephine Egan; Adrian S Dobs
Relation between duration of androgen deprivation therapy and degree of insulin resistance in men with prostate cancer.
Archives of internal medicine 2007;167(6):612-3.
2007: Gopal K Bajaj; Zhe Zhang; Elizabeth Garrett-Mayer; Renee Drew; Victoria Sinibaldi; Roberto Pili; Samuel R Denmeade; Michael A Carducci; Mario A Eisenberger; Theodore L DeWeese
Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapy.
Urology 2007;69(3):526-31.
2007: Tomasz M Beer; Christopher W Ryan; Peter M Venner; Daniel P Petrylak; Gurkamal S Chatta; J Dean Ruether; Charles H Redfern; Louis Fehrenbacher; Mansoor N Saleh; David M Waterhouse; Michael A Carducci; Daniel Vicario; Robert Dreicer; Celestia S Higano; Frederick R Ahmann; Kim N Chi; W David Henner; Alan Arroyo; Fong W Clow
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(6):669-74.
2007: JANET WALCZAK; Michael A Carducci
Prostate cancer: a practical approach to current management of recurrent disease.
Mayo Clinic proceedings. Mayo Clinic 2007;82(2):243-9.
2007: Sushant Kachhap; Dennis Faith; Zheng (David) Qian; Shabana Shabbeer; Nathan L Galloway; Roberto Pili; Samuel R Denmeade; Angelo M DeMarzo; Michael A Carducci
The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherin.
PloS one 2007;2(9):e844.
2007: Wells A Messersmith; MICHELLE RUDEK-RENAUT; Sharyn D Baker; Ming Zhao; Connie Collins; A Dimitrios Colevas; Ross C Donehower; Michael A Carducci; Antonio C Wolff
Phase I study of continuous weekly dosing of dimethylamino benzoylphenylurea (BPU) in patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 2007;43(1):78-86.
2006: Ian M Thompson; Peter R Carroll; Michael A Carducci
Recommendations for defining and treating high risk localized prostate cancer.
The Journal of urology 2006;176(6 Pt 2):S6-S10; quiz S3-5.
2006: Wells A Messersmith; Manuel Hidalgo; Michael A Carducci; S Gail Eckhardt
Novel targets in solid tumors: MEK inhibitors.
Clinical advances in hematology & oncology : H&O 2006;4(11):831-6.
2006: Robert J Motzer; Graeme B Bolger; Barry Boston; Michael A Carducci; Mayer Fishman; Steven L Hancock; Ralph J Hauke; Gary R Hudes; Eric Jonasch; Philip W Kantoff; Timothy M Kuzel; Paul H Lange; Ellis G Levine; Chris Logothetis; Kim A Margolin; Kamal S Pohar; Bruce G Redman; Cary N Robertson; Wolfram E Samlowski; Joel Sheinfeld
Kidney cancer. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4(10):1072-81.
2006: Robert J Motzer; Graeme B Bolger; Barry Boston; Michael A Carducci; Mayer Fishman; Steven L Hancock; Ralph J Hauke; Gary R Hudes; Eric Jonasch; Philip W Kantoff; Timothy M Kuzel; Paul H Lange; Ellis G Levine; Chris Logothetis; Kim A Margolin; Kamal S Pohar; Bruce G Redman; Cary N Robertson; Wolfram E Samlowski; Joel Sheinfeld
Testicular cancer. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4(10):1038-58.
2006: Jill Gilbert; Michael A Carducci; Sharyn D Baker; Elizabeth Dees; Ross C Donehower
A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies.
Investigational new drugs 2006;24(6):499-508.
2006: Marcello Maggio; Amanda Blackford; Dennis Taub; Michael A Carducci; Alessandro Ble; E Jeffrey Metter; Milena Braga-Basaria; Adrian S Dobs; Shehzad Basaria
Circulating inflammatory cytokine expression in men with prostate cancer undergoing androgen deprivation therapy.
Journal of andrology 2006;27(6):725-8.
2006: Michael A Carducci; Antonio Jimeno
Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 2):6296s-6300s.
2006: Allan Lipton; James R Berenson; Jean-Jacques Body; Brendan F Boyce; Oyvind S Bruland; Michael A Carducci; Charles S Cleeland; Denis R Clohisy; Robert E Coleman; Richard J Cook; Theresa A Guise; Roger N Pearse; Trevor J Powles; Michael J Rogers; David G Roodman; Matthew R Smith; Larry J Suva; Robert L Vessella; Katherine N Weilbaecher; Laura King
Advances in treating metastatic bone cancer: summary statement for the First Cambridge Conference.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 2):6209s-6212s.
2006: Zheng (David) Qian; Sushant Kachhap; Spencer J Collis; Hendrik Verheul; Michael A Carducci; Peter Atadja; Roberto Pili
Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha.
Cancer research 2006;66(17):8814-21.
2006: Michael H Levy; Anthony Back; Sadaf Bazargan; Costantino Benedetti; J Andrew Billings; Susan D Block; Eduardo Bruera; Michael A Carducci; Sydney M Dy; Catherine Eberle; Kathleen M Foley; Juan-Diego Harris; Sara J Knight; Robert Milch; Michelle Rhiner; Neal E Slatkin; David Spiegel; Linda Sutton; Susan G Urba; Jamie H Von Roenn; Sharon M Weinstein
Palliative care. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2006;4(8):776-818.
2006: Michael A Carducci; Luna Musib; Merrill S Kies; Roberto Pili; Mylene Truong; Julie R Brahmer; Patricia Cole; Rana Sullivan; Jeanne Riddle; Jill Schmidt; Nathan Enas; Vikram Sinha; Donald E Thornton; Roy S Herbst
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(25):4092-9.
2006: Milena Braga-Basaria; Denis C Muller; Michael A Carducci; Adrian S Dobs; Shehzad Basaria
Lipoprotein profile in men with prostate cancer undergoing androgen deprivation therapy.
International journal of impotence research 2006;18(5):494-8.
2006: Milena Braga-Basaria; Adrian S Dobs; Denis C Muller; Michael A Carducci; Majnu John; Josephine Egan; Shehzad Basaria
Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(24):3979-83.
2006: Victoria Sinibaldi; Kathy Elza-Brown; Jill Schmidt; Mario A Eisenberger; Eli Rosenbaum; Samuel R Denmeade; Roberto Pili; JANET WALCZAK; Sharyn D Baker; Marianna Zahurak; Michael A Carducci
Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma.
American journal of clinical oncology 2006;29(4):395-8.
2006: Elisabeth Iljas Heath; Michael A Carducci
New targets in the management of prostate cancer.
Hematology/oncology clinics of North America 2006;20(4):985-99, xi.
2006: Qinghua Xia; Jennifer Sung; Wasim H Chowdhury; Chien-Lun Chen; Naseruddin Höti; Shabana Shabbeer; Michael A Carducci; Ronald Rodriguez
Chronic administration of valproic acid inhibits prostate cancer cell growth in vitro and in vivo.
Cancer research 2006;66(14):7237-44.
2006: Eric J Small; Michael A Carducci; James M Burke; Ronald Rodriguez; Lawrence Fong; Lynn Van Ummersen; De-Chao Yu; Junko Aimi; Dale Ando; Peter Working; David Kirn; George Wilding
A phase I trial of intravenous CG7870, a replication-selective, prostate-specific antigen-targeted oncolytic adenovirus, for the treatment of hormone-refractory, metastatic prostate cancer.
Molecular therapy : the journal of the American Society of Gene Therapy 2006;14(1):107-17.
2006: Steven D Gore; Stephen B Baylin; Elizabeth Sugar; Hetty Carraway; Carole B Miller; Michael A Carducci; Michael R Grever; Oliver Galm; Tianna Dauses; Judith E Karp; MICHELLE RUDEK-RENAUT; Ming Zhao; B Douglas Smith; Jasper Manning; Anchalee Jiemjit; George J Dover; Abbie Mays; James Zwiebel; Anthony J Murgo; Li-Jun Weng; James G Herman
Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.
Cancer research 2006;66(12):6361-9.
2006: Lisa J Green; Philip Marder; Chad Ray; Carolyn A Cook; Susan Jaken; Luna Musib; Roy S Herbst; Michael A Carducci; Carolyn D Britten; Michele Basche; S Gail Eckhardt; Donald Thornton
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(11 Pt 1):3408-15.
2006: Jonathan W Simons; Michael A Carducci; Bahar Mikhak; Michael Lim; Barbara A Biedrzycki; Flavia Borellini; Shirley M Clift; Kristen M Hege; Dale Ando; Steven Piantadosi; Richard Mulligan; William G Nelson
Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(11 Pt 1):3394-401.
2006: Antonio Jimeno; Michael A Carducci
Atrasentan: a rationally designed targeted therapy for cancer.
Drugs of today (Barcelona, Spain : 1998) 2006;42(5):299-312.
2006: Andrew J Armstrong; Michael A Carducci
New drugs in prostate cancer.
Current opinion in urology 2006;16(3):138-45.
2006: Robert Gray; Judith Manola; Scott Saxman; John Wright; Janice Dutcher; Michael Atkins; Michael A Carducci; William A See; Christopher Sweeney; Glenn Liu; Mark Stein; Robert Dreicer; George Wilding; Robert S DiPaola
Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):1966-9.
2006: Wells A Messersmith; Sharyn D Baker; Lance K Lassiter; Rana A Sullivan; Kimberly Dinh; Virna I Almuete; John J Wright; Ross C Donehower; Michael A Carducci; Deborah K Armstrong
Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(4):1270-5.
2006: Shehzad Basaria; Denis C Muller; Michael A Carducci; Josephine Egan; Adrian S Dobs
Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
Cancer 2006;106(3):581-8.
2006: Madeline Kortenhorst; Michael A Carducci; Shabana Shabbeer
Acetylation and histone deacetylase inhibitors in cancer.
Cellular oncology : the official journal of the International Society for Cellular Oncology 2006;28(5-6):191-222.
2005: Michael Huie; Michael A Carducci; Glenn Liu; George Wilding; Rebecca Marnocha; Miguel Izquierda; James P Thomas
Phase I study of piritrexim and gemcitabine in patients with advanced solid tumors.
American journal of clinical oncology 2005;28(6):613-7.
2005: Eli Rosenbaum; Marianna Zahurak; Victoria Sinibaldi; Michael A Carducci; Roberto Pili; Menachem Laufer; Theodore L DeWeese; Mario A Eisenberger
Marimastat in the treatment of patients with biochemically relapsed prostate cancer: a prospective randomized, double-blind, phase I/II trial.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(12):4437-43.
2005: Edward A Sausville; Michael A Carducci
Making bad cells go good: the promise of epigenetic therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(17):3875-6.
2005: MICHELLE RUDEK-RENAUT; Ming Zhao; Ping He; Carol Hartke; Jill Gilbert; Steven D Gore; Michael A Carducci; Sharyn D Baker
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(17):3906-11.
2005: Andrew J Armstrong; Michael A Carducci
Advanced prostate cancer: the future.
The Canadian journal of urology 2005;12 Suppl 2():42-7.
2005: Antonio Jimeno; Michael A Carducci
Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer.
Expert review of anticancer therapy 2005;5(3):419-27.
2005: Michael A Carducci
What is more exciting? The activity of docetaxel in early prostate cancer or the successful collaboration between urologists and medical oncologists to complete a study in early prostate cancer?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(15):3304-7.
2005: Michael A Carducci; Peter R Carroll
Multidisciplinary management of advanced prostate cancer: changing perspectives on referring patients and enhancing collaboration between oncologists and urologists in clinical trials.
Urology 2005;65(5 Suppl):18-22; discussion 22.
2005: Andrew J Armstrong; Michael A Carducci
Chemotherapy for advanced prostate cancer: results of new clinical trials and future studies.
Current oncology reports 2005;7(3):220-7.
2005: Andrew J Armstrong; Michael A Carducci
Novel therapeutic approaches to advanced prostate cancer.
Clinical advances in hematology & oncology : H&O 2005;3(4):271-82.
2005: Surasak Phuphanich; Sharyn D Baker; Stuart A Grossman; Kathryn Carson; Mark R Gilbert; Joy D Fisher; Michael A Carducci
Oral sodium phenylbutyrate in patients with recurrent malignant gliomas: a dose escalation and pharmacologic study.
Neuro-oncology 2005;7(2):177-82.
2005: ILENE BROWNER; Michael A Carducci
Palliative chemotherapy: historical perspective, applications, and controversies.
Seminars in oncology 2005;32(2):145-55.
2005: Albert J ten Tije; Jaap Verweij; Michael A Carducci; Wilfried J Graveland; Theresa Rogers; Tatjana Pronk; M P Verbruggen; Fitzroy W Dawkins; Sharyn D Baker
Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(6):1070-7.
2005: Shabana Shabbeer; Michael A Carducci
Focus on deacetylation for therapeutic benefit.
IDrugs : the investigational drugs journal 2005;8(2):144-54.
2005: Elizabeth Dees; Sharyn D Baker; Seamus O'Reilly; MICHELLE RUDEK-RENAUT; Susan B Davidson; Cheryl Aylesworth; Kathy Elza-Brown; Michael A Carducci; Ross C Donehower
A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(2 Pt 1):664-71.
2005: Robert J Motzer; Michael A Carducci; Mayer Fishman; Steven L Hancock; Ralph J Hauke; Gary R Hudes; Philip Kantoff; Timothy M Kuzel; Paul H Lange; Ellis G Levine; Chris Logothetis; Kim A Margolin; Roberto Pili; Kamal S Pohar; Bruce G Redman; Sylvia Richey; Cary N Robertson; Wolfram E Samlowski; Joel Sheinfeld; Donald A Urban
Kidney cancer. Clinical practice guidelines.
Journal of the National Comprehensive Cancer Network : JNCCN 2005;3(1):84-93.
2005: Robert J Motzer; Robert R Bahnson; Barry Boston; Michael A Carducci; Mayer Fishman; Steven L Hancock; Ralph J Hauke; Gary R Hudes; Philip Kantoff; Timothy M Kuzel; Paul H Lange; Ellis G Levine; Chris Logothetis; Kim A Margolin; Bruce G Redman; Sylvia Richey; Cary N Robertson; Wolfram E Samlowski; Joel Sheinfeld; Donald A Urban
Testicular cancer. Clinical practice guidelines.
Journal of the National Comprehensive Cancer Network : JNCCN 2005;3(1):52-76.
2005: Kuo-Shyan Lin; Andrew Luu; Kwamena Baidoo; Hossein Hashemzadeh-Gargari; Ming-Kai Chen; Kenneth Brenneman; Roberto Pili; Martin G Pomper; Michael A Carducci; Henry N Wagner
A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation.
Bioconjugate chemistry 2005;16(1):43-50.
2004: Ming Zhao; MICHELLE RUDEK-RENAUT; Ping He; Carol Hartke; Steven D Gore; Michael A Carducci; Sharyn D Baker
Quantification of 5-azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;813(1-2):81-8.
2004: Sharyn D Baker; Ron van Schaik; Laurent P Rivory; Albert J ten Tije; Kimberly Dinh; Wilfried J Graveland; Paul W Schenk; Kellie A Charles; Stephen J Clarke; Michael A Carducci; William P McGuire; Fitzroy W Dawkins; Hans Gelderblom; Jaap Verweij; Alex Sparreboom
Factors affecting cytochrome P-450 3A activity in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(24):8341-50.
2004: Joshi J Alumkal; Michael A Carducci
Early use of chemotherapy in conjunction with radical prostatectomy.
Clinical prostate cancer 2004;3(3):144-9.
2004: Masood A Khan; Michael A Carducci; Alan W Partin
Docetaxel in androgen-independent prostate cancer: an update.
BJU international 2004;94(9):1209-10.
2004: Antonio Jimeno; Michael A Carducci
Atrasentan: targeting the endothelin axis in prostate cancer.
Expert opinion on investigational drugs 2004;13(12):1631-40.
2004: Kuo-Shyan Lin; Andrew Luu; Kwamena Baidoo; Hossein Hashemzadeh-Gargari; Ming-Kai Chen; Roberto Pili; Martin G Pomper; Michael A Carducci; Henry N Wagner
A new high affinity technetium analogue of bombesin containing DTPA as a pharmacokinetic modifier.
Bioconjugate chemistry 2004;15(6):1416-23.
2004: Donald S Kaufman; Michael A Carducci; Tim M Kuzel; Mary B Todd; William K Oh; Matthew R Smith; Zhishen Ye; Steven J Nicol; Walter M Stadler
A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer.
Urologic oncology 2004;22(5):393-7.
2004: Arthur Zelent; Samuel Waxman; Michael A Carducci; John Wright; James Zweibel; Steven D Gore
State of the translational science: summary of Baltimore workshop on gene re-expression as a therapeutic target in cancer January 2003.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(14):4622-9.
2004: Jill Gilbert; Steven D Gore; James G Herman; Michael A Carducci
The clinical application of targeting cancer through histone acetylation and hypomethylation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(14):4589-96.
2004: Michael A Carducci
The healing power of hope.
The Johns Hopkins medical letter health after 50 2004;17(5):5.
2004: Sharyn D Baker; Ming Zhao; Carlton K K Lee; Jaap Verweij; Yelena Zabelina; Julie R Brahmer; Antonio C Wolff; Alex Sparreboom; Michael A Carducci
Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(6):1976-83.
2004: Howard I Scher; Mario A Eisenberger; Anthony V D'Amico; Susan Halabi; Eric J Small; Michael J Morris; Michael W Kattan; Mack Roach; Philip W Kantoff; Kenneth J Pienta; Michael A Carducci; David B Agus; Susan F Slovin; Glenn Heller; W Kevin Kelly; Paul H Lange; Daniel P Petrylak; William Berg; Celestia S Higano; George Wilding; Judd W Moul; Alan W Partin; Christopher Logothetis; Howard R Soule
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(3):537-56.
2004: Sharyn D Baker; Ming Zhao; Ping He; Michael A Carducci; Jaap Verweij; Alex Sparreboom
Simultaneous analysis of docetaxel and the formulation vehicle polysorbate 80 in human plasma by liquid chromatography/tandem mass spectrometry.
Analytical biochemistry 2004;324(2):276-84.
2004: Usha Sunkara; JANET WALCZAK; Lori Summerson; Theresa Rogers; Mario A Eisenberger; Samuel R Denmeade; Roberto Pili; Carol Ann Huff; Victoria Sinibaldi; Michael A Carducci
A phase II trial of temozolomide and IFN-alpha in patients with advanced renal cell carcinoma.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2004;24(1):37-41.
2004: Mario A Eisenberger; Menachem Laufer; Nicholas J Vogelzang; Oliver Sartor; Donald Thornton; Blake Lee Neubauer; Victoria Sinibaldi; Gary Lieskovsky; Michael A Carducci; Marianna Zahurak; Derek Raghavan
Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action.
Urology 2004;63(1):114-9.
2003: JANET WALCZAK; Michael A Carducci
Phase 3 randomized trial evaluating second-line hormonal therapy versus docetaxel-estramustine combination chemotherapy on progression-free survival in asymptomatic patients with a rising prostate-specific antigen level after hormonal therapy for prostate cancer: an Eastern Cooperative Oncology Group (E1899), Intergroup/Clinical Trials Support Unit study.
Urology 2003;62 Suppl 1():141-6.
2003: Masood A Khan; Michael A Carducci; Alan W Partin
The evolving role of docetaxel in the management of androgen independent prostate cancer.
The Journal of urology 2003;170(5):1709-16.
2003: Lance K Lassiter; Michael A Carducci
Endothelin receptor antagonists in the treatment of prostate cancer.
Seminars in oncology 2003;30(5):678-88.
2003: Antonio C Wolff; Ross C Donehower; M Katherine Carducci; Michael A Carducci; Julie R Brahmer; Yelena Zabelina; Matthews O Bradley; Forrest H Anthony; Charles S Swindell; Philip A Witman; Nigel L Webb; Sharyn D Baker
Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profile.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3589-97.
2003: Alexander I Spira; Michael A Carducci
Differentiation therapy.
Current opinion in pharmacology 2003;3(4):338-43.
2003: Eli Rosenbaum; Michael A Carducci
Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges.
Expert opinion on pharmacotherapy 2003;4(6):875-87.
2003: Joel B Nelson; Azmi A Nabulsi; Nicholas J Vogelzang; Jurgen Breul; Bernard A Zonnenberg; Danai D Daliani; Claude C Schulman; Michael A Carducci
Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan.
The Journal of urology 2003;169(3):1143-9.
2003: Michael A Carducci; Robert J Padley; Jurgen Breul; Nicholas J Vogelzang; Bernard A Zonnenberg; Danai D Daliani; Claude C Schulman; Azmi A Nabulsi; Rod A Humerickhouse; Mark A Weinberg; Jennifer L Schmitt; Joel B Nelson
Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):679-89.
2003: Robert Dreicer; Michael A Carducci
E-1899: An Eastern Cooperative Oncology Group Study Comparing Ketoconazole Plus Hydrocortisone with Docetaxel Plus Estramustine for Asymptomatic, Androgen-Independent, Nonmetastatic Prostate Cancer Patients with Rising PSA Levels.
Reviews in urology 2003;5 Suppl 2():S35-41.
2003: Michael A Carducci
Prostate cancer update: advanced disease.
Reviews in urology 2003;5 Suppl 6():S47-53.
2003: Robert Dreicer; Michael A Carducci
E-1899: An Eastern Cooperative Oncology Group Study Comparing Ketoconazole Plus Hydrocortisone with Docetaxel Plus Estramustine for Asymptomatic, Androgen-Independent, Nonmetastatic Prostate Cancer Patients with Rising PSA Levels.
Reviews in urology 2003;5 Suppl 3():S52-8.
2002: Elisabeth Iljas Heath; Theodore L DeWeese; Alan W Partin; Angelo M DeMarzo; John Groopman; William G Nelson; Steven Piantadosi; Ron Lieberman; Michael A Carducci
The design of a randomized, placebo-controlled trial of celecoxib in preprostatectomy men with clinically localized adenocarcinoma of the prostate.
Clinical prostate cancer 2002;1(3):182-7.
2002: JANET WALCZAK; Michael A Carducci
Pharmacological treatments for prostate cancer.
Expert opinion on investigational drugs 2002;11(12):1737-48.
2002: Francesco Lo Coco; Arthur Zelent; Adi Kimchi; Michael A Carducci; Steven D Gore; Samuel Waxman
Progress in differentiation induction as a treatment for acute promyelocytic leukemia and beyond.
Cancer research 2002;62(19):5618-21.
2002: Shehzad Basaria; John Lieb; Alice M Tang; Theodore L DeWeese; Michael A Carducci; Mario A Eisenberger; Adrian S Dobs
Long-term effects of androgen deprivation therapy in prostate cancer patients.
Clinical endocrinology 2002;56(6):779-86.
2002: E Scott Kopetz; Joel B Nelson; Michael A Carducci
Endothelin-1 as a target for therapeutic intervention in prostate cancer.
Investigational new drugs 2002;20(2):173-82.
2002: Ying Li; John McCadden; Fernando Ferrer; Mark Kruszewski; Michael A Carducci; Jonathan Simons; Ronald Rodriguez
Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.
Cancer research 2002;62(9):2576-82.
2002: Michael A Carducci; Joel B Nelson; M Kathy Bowling; Theresa Rogers; Mario A Eisenberger; Victoria Sinibaldi; Ross C Donehower; Terri L Leahy; Robert A Carr; Jeffrey D Isaacson; Todd J Janus; Amy Andre; Balakrishna S Hosmane; Robert J Padley
Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2171-80.
2002: Victoria Sinibaldi; Michael A Carducci; Sandra Moore-Cooper; Menachem Laufer; Marianna Zahurak; Mario A Eisenberger
Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
Cancer 2002;94(5):1457-65.
2001: H G van der Poel; J McCadden; G W Verhaegh; M Kruszewski; F Ferrer; J A Schalken; Michael A Carducci; Ronald Rodriguez
A novel method for the determination of basal gene expression of tissue-specific promoters: an analysis of prostate-specific promoters.
Cancer gene therapy 2001;8(12):927-35.
2001: Michael H Levy; Sharon M Weinstein; Michael A Carducci
NCCN: Palliative care.
Cancer control : journal of the Moffitt Cancer Center 2001;8(6 Suppl 2):66-71.
2001: Michael A Carducci
NCCN: New chemotherapeutic approaches to hormone refractory prostate cancer.
Cancer control : journal of the Moffitt Cancer Center 2001;8(6 Suppl 2):62-5.
2001: Theodore L DeWeese; H van der Poel; Shidong Li; Bahar Mikhak; R Drew; M Goemann; Ulrike M Hamper; R DeJong; Nicholas Detorie; Ronald Rodriguez; T Haulk; Angelo M DeMarzo; Steven Piantadosi; De-Chao Yu; Yu Chen; DR Henderson; Michael A Carducci; William G Nelson; Jonathan W Simons
A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy.
Cancer research 2001;61(20):7464-72.
2001: Elisabeth Iljas Heath; Seamus O'Reilly; R Humphrey; P Sundaresan; Ross C Donehower; SE Sartorius; M John Kennedy; Deborah K Armstrong; Michael A Carducci; J M Sorensen; K Kumor; S Kennedy; Louise B. Grochow
Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2001;48(4):269-74.
2001: Michael A Carducci; J Gilbert; M Kathy Bowling; Dennis A Noe; Mario A Eisenberger; Victoria Sinibaldi; Yelena Zabelina; Tian Ling Chen; Louise B. Grochow; Ross C Donehower
A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(10):3047-55.
2001: J Gilbert; Sharyn D Baker; M Kathy Bowling; Louise B. Grochow; William D Figg; Yelena Zabelina; Ross C Donehower; Michael A Carducci
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2292-300.
2001: William W Roberts; E J Bergstralh; M L Blute; J M Slezak; Michael A Carducci; Misop Han; Jonathan I Epstein; Mario A Eisenberger; Patrick C Walsh; Alan W Partin
Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy.
Urology 2001;57(6):1033-7.
2001: JANET WALCZAK; H Wood; G Wilding; T Williams; C W Bishop; Michael A Carducci
Prostate cancer prevention strategies using antiproliferative or differentiating agents.
Urology 2001;57(4 Suppl 1):81-5.
2001: Roberto Pili; M P Kruszewski; B W Hager; J Lantz; Michael A Carducci
Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis.
Cancer research 2001;61(4):1477-85.
2000: Steven D Gore; Michael A Carducci
Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors.
Expert opinion on investigational drugs 2000;9(12):2923-34.
2000: Menachem Laufer; Samuel R Denmeade; Victoria Sinibaldi; Michael A Carducci; Mario A Eisenberger
Complete androgen blockade for prostate cancer: what went wrong?
The Journal of urology 2000;164(1):3-9.
2000: ZP Wang; Mario A Eisenberger; Michael A Carducci; Alan W Partin; Howard I Scher; PO Ts'o
Identification and characterization of circulating prostate carcinoma cells.
Cancer 2000;88(12):2787-95.
2000: D Kaufman; D Raghavan; Michael A Carducci; E G Levine; B Murphy; Joseph Aisner; T Kuzel; S Nicol; William K Oh; W Stadler
Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(9):1921-7.
2000: Joel B Nelson; Michael A Carducci
The role of endothelin-1 and endothelin receptor antagonists in prostate cancer.
BJU international 2000;85 Suppl 2():45-8.
2000: Menachem Laufer; Charles R Pound; Michael A Carducci; Mario A Eisenberger
Management of patients with rising prostate-specific antigen after radical prostatectomy.
Urology 2000;55(3):309-15.
2000: Michael A Carducci
Adjuvant chemotherapy for T3 prostate cancer: not ready for prime time.
Urology 2000;55(2):157-60.
2000: William G Nelson; Jonathan W Simons; Bahar Mikhak; J F Chang; Angelo M DeMarzo; Michael A Carducci; M Kim; CE Weber; AA Baccala; M A Goeman; Shirley Clift; Dale Ando; Hyam I Levitsky; LK Cohen; M G Sanda; Richard C Mulligan; Alan W Partin; H Ballentine Carter; Steven Piantadosi; Fray F Marshall
Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Cancer chemotherapy and pharmacology 2000;46 Suppl():S67-72.
2000: Joel B Nelson; Michael A Carducci
Small bioactive peptides and cell surface peptidases in androgen-independent prostate cancer.
Cancer investigation 2000;18(1):87-96.
1999: Glenn J Bubley; Michael A Carducci; William Dahut; Nancy A Dawson; Danai D Daliani; Mario A Eisenberger; William D Figg; B Freidlin; Susan Halabi; Gary R Hudes; Maha Hussain; Richard S. Kaplan; C Myers; William K Oh; Daniel P Petrylak; Eddie Reed; B Roth; Oliver Sartor; Howard I Scher; J Simons; Victoria Sinibaldi; E J Small; M R Smith; D L Trump; G Wilding
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3461-7.
1999: Jonathan W Simons; Bahar Mikhak; J F Chang; Angelo M DeMarzo; Michael A Carducci; M Lim; CE Weber; AA Baccala; M A Goemann; Shirley Clift; Dale Ando; Hyam I Levitsky; LK Cohen; M G Sanda; Richard C Mulligan; Alan W Partin; H Ballentine Carter; Steven Piantadosi; Fray F Marshall; William G Nelson
Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
Cancer research 1999;59(20):5160-8.
1999: Menachem Laufer; Victoria Sinibaldi; Michael A Carducci; Mario A Eisenberger
Rapid disease progression after the administration of bicalutamide in patients with metastatic prostate cancer.
Urology 1999;54(4):745.
1999: Victoria Sinibaldi; Michael A Carducci; Menachem Laufer; Mario A Eisenberger
Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer.
Seminars in oncology 1999;26(5 Suppl 17):45-8.
1999: Michael A Carducci; Theodore L DeWeese; Joel B Nelson
Prostate-specific antigen and other markers of therapeutic response.
The Urologic clinics of North America 1999;26(2):291-302, viii.
1999: Michael A Carducci; Steven Piantadosi; Charles R Pound; Jonathan I Epstein; J W Simons; Fray F Marshall; Alan W Partin
Nuclear morphometry adds significant prognostic information to stage and grade for renal cell carcinoma.
Urology 1999;53(1):44-9.
1998: C G Healy; J W Simons; Michael A Carducci; Theodore L DeWeese; M Bartkowski; K P Tong; WE Bolton
Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer.
Cytometry 1998;32(2):109-19.
1998: Michael A Carducci; Michael A Choti; NE Maestri; Saul W Brusilow
Allopurinol-induced pyrimidinuria in cancer patients.
In vivo (Athens, Greece) 1998;12(3):271-4.
1998: M A Pelidis; Michael A Carducci; Jonathan W Simons
Cytotoxic effects of sodium phenylbutyrate on human neuroblastoma cell lines.
International journal of oncology 1998;12(4):889-93.
1997: Jonathan W Simons; Elizabeth M Jaffee; CE Weber; Hyam I Levitsky; William G Nelson; Michael A Carducci; A J Lazenby; LK Cohen; C C Finn; Shirley Clift; K M Hauda; Lisa A Beck; KM Leiferman; A H Owens; Steven Piantadosi; Glenn Dranoff; Richard C Mulligan; Drew M Pardoll; Fray F Marshall
Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer.
Cancer research 1997;57(8):1537-46.
1996: Michael A Carducci; Theodore L DeWeese; William G Nelson; Jonathan W Simons; Victoria Sinibaldi; Mario A Eisenberger
Prostate cancer treatment strategies based on tumor-specific biological principles: future directions.
Seminars in oncology 1996;23(6 Suppl 14):56-62.
1996: Michael A Carducci; R A Abrams; Charles J Yeo; Ralph Hruban; Marianna Zahurak; John L Cameron; Louise B. Grochow
Early evaluation of abdominal/hepatic irradiation and 5-fluorouracil/leucovorin infusion after pancreaticoduodenectomy.
International journal of radiation oncology, biology, physics 1996;35(1):143-50.
1996: Michael A Carducci; Joel B Nelson; Kirk M Chan-Tack; S R Ayyagari; W H Sweatt; P A Campbell; William G Nelson; Jonathan W Simons
Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(2):379-87.
1996: Michael A Carducci; J W Simons
Renal, bladder, and prostate cancers: gene therapy.
Cancer treatment and research 1996;88():219-34.
1995: D A Twillie; Mario A Eisenberger; Michael A Carducci; W S Hseih; William Kim; Jonathan W Simons
Interleukin-6: a candidate mediator of human prostate cancer morbidity.
Urology 1995;45(3):542-9.